Mind Medicine (MindMed) Stock (NASDAQ:MNMD)

Ownership Financials Chart

Previous Close

$7.72

52W Range

$4.70 - $10.44

50D Avg

$7.02

200D Avg

$6.85

Market Cap

$611.98M

Avg Vol (3M)

$1.12M

Beta

2.88

Div Yield

MNMD Company Profile

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Nov 15, 2016

Website

MNMD Performance

MNMD Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-103.92M	$-93.87M	$-66.33M
Net Income	$-108.68M	$-95.73M	$-47.26M
EBITDA	$-103.92M	$-92.57M	$-53.57M
Basic EPS	$-1.54	$-2.44	$-1.53
Diluted EPS	$-0.15	$-2.44	$-1.53

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q1 24May 08, 24 | 4:30 PM

Q3 23Nov 02, 23 | 4:30 PM

Q2 23Aug 03, 23 | 4:30 PM

Peer Comparison

Ticker	Company
ATAI	Atai Life Sciences N.V.
FBIO	Fortress Biotech, Inc.
GHRS	GH Research PLC
CMPS	COMPASS Pathways plc
CLOV	Clover Health Investments, Corp.